Clinical trialsCompany release

AIM ImmunoTech pitches Ampligen as add-on to RAS inhibitor in pancreatic cancer

🇺🇸 AIM ImmunoTech Inc. (AIM) · Thu 05 Nov 2026

An investor presentation proposes pairing the investigational TLR3 agonist with Revolution Medicines' daraxonrasib, though no trial of the combination has been established.

AIM ImmunoTech published an investor presentation on 5 November 2026 arguing that its investigational TLR3 agonist Ampligen (rintatolimod) could complement Revolution Medicines' RAS inhibitor daraxonrasib in pancreatic cancer.

The company repeated earlier observations from a named-patient programme in the Netherlands. The summary of the item does not give further detail on those observations.

AIM said topline results from its Phase 2 DURIPANC study, which tests Ampligen with durvalumab, are expected in the first quarter of 2027. Further analyses are planned for the third quarter of 2027.

The daraxonrasib pairing is a proposed strategy only and is not an established clinical trial. Ampligen is not approved by the US Food and Drug Administration for pancreatic cancer.

What it means for your team

  • Treat the daraxonrasib combination as a company hypothesis: no trial has been established, and the summary gives no efficacy or safety data for it.
  • Ampligen has no FDA approval in pancreatic cancer, so any use remains investigational or through named-patient access.
  • The key near-term datapoint is DURIPANC topline data, expected in Q1 2027, with more analyses in Q3 2027.

Company's press release (SEC filing): AIM ImmunoTech Inc. ↗

Article written by VigiEye from the official source (AIM ImmunoTech Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →